{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Small-Cell+Lung+Cancer+%28SCLC%29&page=13", "query": { "condition": "Small-Cell Lung Cancer (SCLC)", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 3989, "total_pages": 399, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Small-Cell+Lung+Cancer+%28SCLC%29&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Small-Cell+Lung+Cancer+%28SCLC%29&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T14:08:41.795Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06875310", "title": "A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Adagrasib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 630, "start_date": "2025-04-24", "completion_date": "2032-04-30", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-15T14:08:41.795Z", "location_count": 52, "location_summary": "Birmingham, Alabama • Springdale, Arkansas • Fullerton, California + 46 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06875310" }, { "nct_id": "NCT04642469", "title": "Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non- Small Cell Lung" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 30, "start_date": "2020-11-30", "completion_date": "2024-01-15", "has_results": true, "last_update_posted_date": "2024-06-25", "last_synced_at": "2026-10-15T14:08:41.795Z", "location_count": 10, "location_summary": "Long Beach, California • Los Angeles, California • Daytona Beach, Florida + 7 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Daytona Beach", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Punta Gorda", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04642469" }, { "nct_id": "NCT03957096", "title": "A Safety Study of SGN-CD47M in Patients With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Soft Tissue Sarcoma", "Colorectal Cancer", "Head and Neck Squamous Cell Carcinoma", "Non-small Cell Lung Carcinoma", "Breast Carcinoma", "Ovarian Carcinoma", "Exocrine Pancreatic Carcinoma", "Gastric Carcinoma", "Melanoma" ], "interventions": [ { "name": "SGN-CD47M", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2019-07-17", "completion_date": "2020-09-14", "has_results": false, "last_update_posted_date": "2020-09-17", "last_synced_at": "2026-10-15T14:08:41.795Z", "location_count": 5, "location_summary": "Cleveland, Ohio • Portland, Oregon • Nashville, Tennessee + 2 more", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03957096" }, { "nct_id": "NCT00950365", "title": "Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bronchioloalveolar Carcinoma", "Large Cell Lung Carcinoma", "Lung Adenocarcinoma", "Recurrent Non-Small Cell Lung Carcinoma", "Stage IIIB Non-Small Cell Lung Cancer", "Stage IV Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pemetrexed Disodium", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Albert Einstein College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2006-04", "completion_date": "2017-11-17", "has_results": true, "last_update_posted_date": "2020-09-16", "last_synced_at": "2026-10-15T14:08:41.795Z", "location_count": 5, "location_summary": "Sacramento, California • Worcester, Massachusetts • The Bronx, New York", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "The Bronx", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00950365" }, { "nct_id": "NCT04348292", "title": "Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Non-Small Cell Carcinoma", "Stage I Lung Cancer AJCC v8", "Stage IA1 Lung Cancer AJCC v8", "Stage IA2 Lung Cancer AJCC v8", "Stage IA3 Lung Cancer AJCC v8", "Stage IB Lung Cancer AJCC v8", "Stage II Lung Cancer AJCC v8", "Stage IIA Lung Cancer AJCC v8", "Stage IIB Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2021-01-22", "completion_date": "2022-11-04", "has_results": true, "last_update_posted_date": "2024-08-22", "last_synced_at": "2026-10-15T14:08:41.795Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04348292" }, { "nct_id": "NCT00093132", "title": "Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Non-small Cell Lung", "Lung Cancer" ], "interventions": [ { "name": "Satraplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agennix", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2004-08", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2012-08-17", "last_synced_at": "2026-10-15T14:08:41.795Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00093132" }, { "nct_id": "NCT05219734", "title": "MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer", "Solid Tumor", "Non Small Cell Lung Cancer", "Colorectal Cancer", "Bladder Cancer" ], "interventions": [ { "name": "Personalized Cancer Monitoring (PCM)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Invitae Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2021-11-29", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2024-03-12", "last_synced_at": "2026-10-15T14:08:41.795Z", "location_count": 2, "location_summary": "Columbus, Indiana • Jacksonville, North Carolina", "locations": [ { "city": "Columbus", "state": "Indiana" }, { "city": "Jacksonville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05219734" }, { "nct_id": "NCT00035516", "title": "A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-small-cell Lung" ], "interventions": [ { "name": "Epothilone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "R-Pharm", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-02", "completion_date": "2004-04", "has_results": false, "last_update_posted_date": "2016-02-10", "last_synced_at": "2026-10-15T14:08:41.795Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Sacramento, California • Miami Beach, Florida + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sacramento", "state": "California" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00035516" }, { "nct_id": "NCT02151981", "title": "AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anticancer Treatment" ], "interventions": [ { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Cross-over to Osimertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 421, "start_date": "2014-08-04", "completion_date": "2023-12-15", "has_results": true, "last_update_posted_date": "2025-01-07", "last_synced_at": "2026-10-15T14:08:41.795Z", "location_count": 21, "location_summary": "Anaheim, California • Orange, California • Santa Rosa, California + 18 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02151981" }, { "nct_id": "NCT00521144", "title": "Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Small Cell Lung Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "obatoclax mesylate", "type": "DRUG" }, { "name": "topotecan hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2007-08", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2015-05-05", "last_synced_at": "2026-10-15T14:08:41.795Z", "location_count": 2, "location_summary": "Baltimore, Maryland • New York, New York", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00521144" } ] }